Key facts
- This page summarizes Joseph J. Ferra Jr.'s Form 4 filing for Elevation Oncology, Inc. (ELEV).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 19 Feb 2025, 16:10.
Joseph J. Ferra Jr. - 15 Feb 2025 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- ELEV
- Reported as of
- 15 Feb 2025
- Net transaction value
- -$6,187
- SEC form
- 4
- Accepted by SEC
- 19 Feb 2025, 16:10:07 UTC
- Prior SEC filing
- 18 Dec 2024
- Next SEC filing
- 18 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Yang, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Joseph J. Ferra Jr. filed Form 4 for Elevation Oncology, Inc. (ELEV) on 19 Feb 2025.
Change
- Previous filing in this sequence was filed on 18 Dec 2024.
- Current net transaction value: -$6,187.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELEV
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +25,000
- Change %
- +23%
- Price
- Shares after
- 134,482
- Date
- 15 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
ELEV
transaction
Common Stock
Tax liability
- Transaction value
- $6,187
- Shares
- -9,211
- Change %
- -6.8%
- Price
- $0.6717
- Shares after
- 125,271
- Date
- 15 Feb 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELEV
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +800,000
- Change %
- Price
- $0.000000
- Shares after
- 800,000
- Date
- 15 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 800,000
- Exercise price
- $0.6717
- Footnotes
- F2
ELEV
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -25,000
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 15 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
The stock option vests as to 25% of the total shares on February 15, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Footnote F3
25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Footnote F4
The RSUs do not expire; they either vest or are canceled prior to the vesting date.